While the first quarter financial report from Sarepta Therapeutics Inc. showed lower revenues and a bigger loss year over year, the stock's value rose 7 percent Thursday after the CEO said he's "encouraged" by the prospects of getting accelerated approval for its lead drug candidate.
http://www.bizjournals.com/boston/blog/bioflash/2013/05/sarepta-up-as-ceo-says-hes.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_45+%28Semiconductor+Industry+News%29
http://www.bizjournals.com/boston/blog/bioflash/2013/05/sarepta-up-as-ceo-says-hes.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_45+%28Semiconductor+Industry+News%29
No comments:
Post a Comment